Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Lung cancer trial aims to zap tumors harder

NCT ID NCT02788461

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This trial tests whether giving a higher radiation dose to the most active parts of a lung tumor can better control the cancer. About 78 people with locally advanced non-small cell lung cancer will receive either standard chemoradiation or chemoradiation with an extra radiation boost. The study will compare how well each approach prevents the cancer from coming back in the chest over two years.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Radiation therapy with or without a boost dose
What this could lead to
If successful, this approach could reduce the chance of lung cancer returning in the chest after standard chemoradiation.
What could go wrong
This is a small, early-phase trial with only 78 participants, so results may not apply to all patients. Higher radiation doses also carry a risk of increased side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 78 people

The number the study aims to enrol. It can still change while the study runs.

Start date

May 2016

Expected to finish

Apr 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients who are at least 18 years old and are able to consent * Patients who will undergo Chemo-RT as primarily modality of treatment * Patients with a primary tumor or node measuring at least 10mm on CT scan * Patients with a PET avid tumor having Standardized Uptake Values (SUV) \> 4 * Patients with Eastern Cooperative Oncology Group (ECOG) status 0-2 within 4 weeks of randomization Exclusion Criteria: * Trimodality patients who have surgery as part of curative treatment * Previous radiotherapy to intended treatment volumes * Active invasive malignancy other than lung cancer * Active pregnancy * Poor respiratory function (Forced Expiratory Volume \< 1.0 or Diffusing Capacity \< 50% age-adjusted normal) * ECOG status \> 2 * Pre-treatment complete blood count/differential showing inadequate bone marrow reserve (absolute neutrophil count \< 1800 cells/mm3 or platelets \< 100 000 cells/mm3 or hemoglobin \< 90g/L), measured within 4 weeks of registration * AST, ALT or total bilirubin \> 2.5 times the upper limit of normal, measured within 4 weeks of registration * Unintentional weight loss \>10% over 3 months within 4 weeks of registration * Severe active co-morbidity defined by: * Significant history of uncontrolled cardiac disease; i.e. uncontrolled hypertension, unstable angina, myocardial infarction within the last 6 months, uncontrolled congestive heart failure, cardiomyopathy with decreased ejection fraction * Transmural myocardial infection requiring intravenous antibiotics at the time of registration * Chronic Obstructive Pulmonary Disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy within 30 days before randomization * Acquired immune deficiency syndrome (AIDS) based on the current Centre for Disease Control definition; note, however, that HIV testing is not required for entry into this protocol

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Non-small cell lung cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • CHU de Quebec - L'Hôtel-Dieu de Québec

    Québec, Quebec, G2L 2Z3, Canada

  • CHUS - Hôpital Fleurimont

    Sherbrooke, Quebec, J1H 5N4, Canada

  • Kingston General Hospital

    Kingston, Ontario, K7L 2V7, Canada

  • London Regional Cancer Program

    London, Ontario, N6A 4L6, Canada

  • McGill University Health Centre, Glen site Cedars Cancer Center

    Montreal, Quebec, H4A 3J1, Canada

  • Princess Margaret Cancer Centre

    Toronto, Ontario, M5G 2M9, Canada

  • Stronach Regional Cancer Centre at Southlake Regional Health Centre

    Newmarket, Ontario, L3Y 2P9, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.